

**ISAR-LEFT MAIN:  
A Randomized Clinical Trial on  
Drug-Eluting Stents for Unprotected  
Left Main Lesions**

Taxus vs Cypher

J. Mehilli, MD

Deutsches Herzzentrum

Technische Universität Munich Germany

# ISAR-LEFT MAIN

Intracoronary Stenting and Angiographic Results:  
Drug-Eluting Stents for Unprotected Coronary Left Main Lesions

607 patients with *unprotected* left main lesions

Clopidogrel 600 mg at least 2h before procedure

Aspirin 500mg i.v.

Paclitaxel-eluting stent

(Taxus)

n=302

Sirolimus-eluting stent

(Cypher)

n=305

Clopidogrel 2x75 mg/day until discharge

75 mg indefinitely


Aspirin 200 mg/day

# Follow-Up Protocol


600 mg Clopidogrel

PCI

ASS 500 mg + heparin with/out GPI (10%) or bivalirudin (15%)




## 2-Yr TLR




No difference


## 2-Yr ST



# 2-Year Mortality



# Death, Myocardial Infarction or Reintervention - 2-Year Follow-Up -



# Summary

Treatment of unprotected LMCA lesions in unselected patients with DES is feasible, safe and effective up to **2 years**

Both Taxus and Cypher stents provide **similar** clinical and angiographic outcomes in this form of coronary artery disease